| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
AN-12-H5 intermediate-1 does not have a direct biological target as it is a chemical building block rather than a pharmacologically active compound. Its purpose is to serve as a precursor in the multi-step organic synthesis of the antiviral agent AN-12-H5. The final compound, AN-12-H5, is noted to have no inhibitory effect on PI4KB activity and only moderate effects on PI3-kinase activity, suggesting its target is distinct from these lipid kinases. As an intermediate, it is not designed to interact with biological macromolecules. It is used in medicinal chemistry to construct more complex molecular architectures.
|
|---|---|
| ln Vitro |
AN-12-H5 intermediate-1 is a chemical intermediate and does not possess direct in vitro biological activity. Its role is in chemical synthesis, not in biological assays. The compound is characterized by its chemical purity, typically >98%, and structural identity confirmed by NMR and HPLC. It is a liquid at room temperature and is soluble in organic solvents like DMSO. It serves as a precursor for the synthesis of AN-12-H5, which would subsequently be evaluated for its antiviral properties in appropriate in vitro models.
|
| ln Vivo |
AN-12-H5 intermediate-1 is not a pharmacologically active compound and does not have direct in vivo activity. It is used solely as a chemical reagent in the laboratory synthesis of the antiviral agent AN-12-H5. The intermediate itself is not administered to animals for any efficacy or safety studies. Any in vivo effects would be associated with the final drug substance, AN-12-H5, after its complete synthesis and formulation. Its storage and handling are optimized for chemical stability to support its use in organic synthesis.
|
| Enzyme Assay |
Standard in vitro enzyme/receptor binding assays are not applicable to AN-12-H5 intermediate-1 as it is a synthetic intermediate without biological activity. Quality control for this compound relies on analytical chemistry techniques. High-Performance Liquid Chromatography (HPLC) is used to assess purity, typically >98%. Nuclear Magnetic Resonance (NMR) spectroscopy confirms the correct stereochemistry and structure. Solubility testing in solvents such as DMSO is performed to guide its handling in chemical reactions. No receptor binding or enzymatic activity assays are performed on this intermediate.
|
| Cell Assay |
Cell-based assays are not performed on AN-12-H5 intermediate-1 as it is not a biologically active compound. It is a chemical reagent used in the laboratory. Its evaluation is limited to chemical purity, identity, and stability. In the context of ADC synthesis, it may be conjugated to other molecules, but the intermediate itself is not tested in cell culture. Handling procedures are based on its chemical properties rather than biological safety profiles. It is stored as a powder at -20°C and is stable for up to three years.
|
| Animal Protocol |
In vivo animal experiments are not conducted with AN-12-H5 intermediate-1. This compound is exclusively a synthetic building block used to produce the active viral inhibitor AN-12-H5. Once AN-12-H5 is synthesized, it may undergo in vivo testing in animal models to evaluate its antiviral efficacy. However, the intermediate itself is not administered to animals. All pharmacological evaluation is deferred to the final compound derived from this intermediate.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable to AN-12-H5 intermediate-1 as it is a synthetic reagent, not a therapeutic agent. The compound is stored as a liquid or powder at -20°C for up to three years and at 4°C for up to two years. In solvent, it is stable at -80°C for six months and at -20°C for one month. It is soluble in DMSO and other organic solvents. These properties are characterized to facilitate its use in chemical synthesis. No ADME studies have been performed as it is not intended for biological administration.
|
| Toxicity/Toxicokinetics |
Toxicological data for AN-12-H5 intermediate-1 are not available as it is a research chemical intermediate. Standard laboratory safety precautions for handling chemical reagents should be followed, including the use of personal protective equipment and working in a well-ventilated area. The compound is not intended for human or animal consumption. Its specific toxicity profile has not been established. Any toxicological assessment would be performed on the final drug candidate, AN-12-H5, not on this synthetic precursor.
|
| References | |
| Additional Infomation |
AN-12-H5 intermediate-1 is a chiral building block for pharmaceutical synthesis. Its molecular formula is C12H21NO5, and its molecular weight is 259.30. It is also known by its systematic name (2S,4S)-1-tert-butyl 2-methyl-4-hydroxypiperidine-1,2-dicarboxylate. It is a key intermediate for the viral inhibitor AN-12-H5 and can be used to synthesize antibody-drug conjugates (ADCs). It is available from chemical suppliers for research use only.
|
| Molecular Formula |
C12H21NO5
|
|---|---|
| Molecular Weight |
259.30
|
| Exact Mass |
259.142
|
| CAS # |
254882-14-9
|
| PubChem CID |
7010734
|
| Appearance |
Colorless to light yellow liquid（Density：1.182±0.06 g/cm3）
|
| Density |
1.182g/cm3
|
| Boiling Point |
352.1ºC at 760 mmHg
|
| Flash Point |
166.8ºC
|
| Vapour Pressure |
2.3E-06mmHg at 25°C
|
| Index of Refraction |
1.495
|
| LogP |
1.159
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
18
|
| Complexity |
323
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC(C)(C)OC(=O)N1CC[C@@H](C[C@H]1C(=O)OC)O
|
| InChi Key |
RNMVWSAJMIKMDY-IUCAKERBSA-N
|
| InChi Code |
InChI=1S/C12H21NO5/c1-12(2,3)18-11(16)13-6-5-8(14)7-9(13)10(15)17-4/h8-9,14H,5-7H2,1-4H3/t8-,9-/m0/s1
|
| Chemical Name |
1-O-tert-butyl 2-O-methyl (2S,4S)-4-hydroxypiperidine-1,2-dicarboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~385.65 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.64 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one),clear solution.
For example, if 1 mL of working solution is to be prepared,you can add 100 μL of 25.0 mg/mL clear DMSO stock solution and add it to 900 μL of 20% SBE-β-CD saline solution and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.64 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one),clear solution. For example, if 1 mL of working solution is to be prepared,you can add 100 μL of 25.0 mg/mL clear DMSO stock solution and add it to 900 μL corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8565 mL | 19.2827 mL | 38.5654 mL | |
| 5 mM | 0.7713 mL | 3.8565 mL | 7.7131 mL | |
| 10 mM | 0.3857 mL | 1.9283 mL | 3.8565 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
